Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7DFBL)

Drug Name
TAK-441 Drug Info
Synonyms
TAK-441; 1186231-83-3; CHEMBL2205230; TAK 441; SCHEMBL1061476; GTPL8200; BCP20946; ZINC43207688; BDBM50401323; LM2094; SB18887; KB-80790; Z-3185; 6-ethyl-N-[1-(2-hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-phenacyl-3-(2,2,2-trifluoroethoxy)pyrrolo[3,2-c]pyridine-2-carboxamide
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
44187367
CAS Number
CAS 1186231-83-3
TTD Drug ID
DM7DFBL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Smoothened homolog (SMO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-04449913 DMSB068 Chronic myelomonocytic leukaemia 2A40 Approved [3]
Vismodegib DM5IXKQ Basal cell carcinoma 2C32 Approved [4]
LDE225 DMM9F25 Basal cell carcinoma 2C32 Phase 2 [5]
LY2940680 DMTJWIQ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
BMS-833923 DM459Q7 Solid tumour/cancer 2A00-2F9Z Phase 1b [6]
LEQ-506 DM5INZP Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
PMID25726713-Compound-49 DM2CT4G N. A. N. A. Patented [8]
PMID25726713-Compound-51 DMF0OW4 N. A. N. A. Patented [8]
PMID25726713-Compound-48 DMSIOUA N. A. N. A. Patented [8]
PMID25726713-Compound-47 DMXE5KM N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Smoothened homolog (SMO) TT8J1S3 SMO_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8200).
2 TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5 Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79.
6 Clinical pipeline report, company report or official report of Exelixis (2011).
7 Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5.
8 Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65.